You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Doxorubicin Hydrochloride Liposome Injection

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Breast Cancer Trial in Shijiazhuang (Doxorubicin HCl liposome injection)

Completed
  • Advanced Breast Cancer
  • Doxorubicin hydrochloride liposome injection
  • Shijiazhuang, China
    The Fourth Hospital of Hebei Medical University
Oct 18, 2023

Locally Advanced or Metastatic Solid Tumors Trial in China (IN10018+PLD, IN10018+PLD+Toripalimab)

Active, not recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Anyang, Henan, China
  • +6 more
Apr 25, 2023

Breast Cancer, Ovarian Cancer Trial in Guangzhou (Doxorubicin Hydrochloride Liposome Injection)

Recruiting
  • Breast Cancer
  • Ovarian Cancer
  • Doxorubicin Hydrochloride Liposome Injection
  • Guangzhou, Guangdong, China
    Sun Yat-Sun Memorial Hospital, Sun Yat-Sun University
Mar 8, 2022

Breast Cancer Trial (Tucatinib, Doxil)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Feb 17, 2023

Advanced Malignant Tumors Trial in Shanghai (doxorubicin HCl liposome injection)

Recruiting
  • Advanced Malignant Tumors
  • doxorubicin hydrochloride liposome injection
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 28, 2022

Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma Trial (DOXIL/CAELYX)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • (no location specified)
Jan 3, 2023

Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)

Recruiting
  • Breast Cancer
  • Pegylated liposomal doxorubicin
  • +5 more
  • Shanghai, China
    Shanghai Pudong Hospital
Dec 11, 2022

Gastric Cancer Trial in Shanghai (PLD, Oxaliplatin, Capecitabine)

Recruiting
  • Gastric Cancer
  • Shanghai, China
    Shanghai General Hospital
Sep 7, 2022

Efficacy and Safety Trial in Zhejiang (pegylated liposomal doxorubicin, paclitaxel, Carboplatin)

Active, not recruiting
  • Efficacy and Safety
  • pegylated liposomal doxorubicin
  • +2 more
  • Zhejiang, Hangzhou, China
    Women's Hospital School Of Medicine Zhejiang University
Jul 14, 2022

Breast Cancer and Ovarian Cancer Trial (SPARC-08-038, Ref-08-038)

Completed
  • Breast Cancer and Ovarian Cancer
  • (no location specified)
Jul 22, 2021

Breast Cancer Trial in Guandong (pegylated liposomal doxorubicin (PLD), cyclophosphamide (C), trastuzumab (H))

Recruiting
  • Breast Cancer
  • pegylated liposomal doxorubicin (PLD)
  • +5 more
  • Guandong, Guangdong, China
    Sunyat-sen Memorial Hospital
Feb 17, 2022

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial (SG001, Doxorubicin HCl liposome injection)

Not yet recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • SG001
  • Doxorubicin hydrochloride liposome injection
  • (no location specified)
Jul 20, 2021

Rhabdomyosarcoma, Child Trial (Doxorubicin Hydrochloride Liposome+Irinotecan, Temozolomide+Irinotecan+Vincristine)

Not yet recruiting
  • Rhabdomyosarcoma, Child
  • (no location specified)
Jul 13, 2022

Bioequivalence Trial in Shijiazhuang (Doxorubicin Hydrochloride Liposome Injection)

Completed
  • Bioequivalence
  • Doxorubicin Hydrochloride Liposome Injection
  • Shijiazhuang, Hebei, China
    Fourth Hospital of Hebei Medical University
Jul 2, 2020

Breast Cancer Trial in Worldwide (Liposomal doxorubicin HCl, Cyclophosphamide, Trastuzumab)

Completed
  • Breast Cancer
  • Liposomal doxorubicin hydrochloride
  • +4 more
  • Kufstein, Austria
  • +21 more
Jun 21, 2022

Ovarian Cancer Trial in Changsha (Doxorubicin Hydrochloride Liposome Injection+carboplatin, paclitaxel +carboplatin)

Recruiting
  • Ovarian Cancer
  • Doxorubicin Hydrochloride Liposome Injection+carboplatin
  • paclitaxel +carboplatin
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Apr 7, 2021

Breast Cancer, Hormone-receptor Positive Breast Cancer Trial in Guangzhou (Pyrotinib, Epirubicin, Doxorubicin Hydrochloride

Recruiting
  • Breast Cancer
  • Hormone-receptor Positive Breast Cancer
  • Guangzhou, Guangdong, China
    Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University
Apr 29, 2021

Acute Myeloid Leukemia Trial in Tianjin (Mitoxantrone HCl liposome injection, Cytarabine, Homoharringtonine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Mitoxantrone hydrochloride liposome injection
  • +3 more
  • (no location specified)
May 29, 2023

Relapsed/Refractory Multiple Myeloma Trial in Suzhou (Mitoxantrone HCl liposome/Dexamethasone/daratumumab)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
May 4, 2023

Acute Myeloid Leukemia Trial in Tianjin (Mitoxantrone HCl liposome injection, Cytarabine, Homoharringtonine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Mitoxantrone hydrochloride liposome injection
  • +3 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jul 1, 2023

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Breast Cancer Trial in Beijing (Mitoxantrone HCl liposome, Capecitabine)

Not yet recruiting
  • Breast Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Dec 1, 2023

Relapsing Multiple Sclerosis Trial in Beijing (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Mitoxantrone Hydrochloride Liposome Injection
  • Beijing, Beijing, China
    Xuanwu Hospital Capital Medical University
Aug 9, 2022

Neuromyelitis Optica Spectrum Disorder Trial (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Neuromyelitis Optica Spectrum Disorder
  • Mitoxantrone Hydrochloride Liposome Injection
  • (no location specified)
Sep 20, 2022

Recurrent Metastatic Nasopharyngeal Carcinoma Trial (Mitoxantrone HCl liposome injection, Capecitabine)

Not yet recruiting
  • Recurrent Metastatic Nasopharyngeal Carcinoma
  • (no location specified)
Jan 29, 2023